Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,580,864
+$1,126,837 QoQ
Shares Held
16,468
+73.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#385
of 1,603 holders
Holding Since
Sep 2020
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Schonfeld Strategic Advisors LLC holds $100,420,553 across 10 Drug Manufacturers - General names. NVS ranks #5 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
240,327 | $48,495,411 | |
| 2 | ABBV |
AbbVie Inc.
|
104,287 | $26,242,780 | |
| 3 | GSK |
GSK plc
|
199,265 | $10,445,471 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
57,030 | $7,205,170 | |
| 5 | NVS |
Novartis AG
This page
|
16,468 | $2,580,864 | |
| 6 | MRK |
Merck & Co., Inc.
|
15,528 | $1,995,348 | |
| 7 | JNJ |
Johnson & Johnson
|
6,461 | $1,640,900 | |
| 8 | SNY |
Sanofi
|
15,897 | $678,166 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,580,864 | 16,468 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,454,027 | 9,519 | Shares | Sole | 2026-05-15 | |
| 2024-12-31 | $6,073,895 | 62,418 | Shares | Sole | 2025-02-14 | |
| 2023-06-30 | $21,372,435 | 211,797 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $9,777,484 | 106,277 | Shares | Sole | 2023-05-15 | |
| 2022-09-30 | $4,840,924 | 63,688 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $12,716,291 | 144,915 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $778,483 | 8,900 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $2,158,992 | 26,400 | Shares | Sole | 2021-11-16 | |
| 2020-09-30 | $288,707 | 3,320 | Shares | Sole | 2020-11-19 | |
| No filing history on record for this holder in this stock. | ||||||